Vertex Pharmaceuticals gears up for its quarterly earnings announcement, with investors and analysts eagerly anticipating the results. After a strong performance last quarter, Vertex is expected to deliver a ten percent year-over-year revenue increase, reaching just over three billion dollars. Adjusted earnings are forecast at four dollars and fifty-eight cents per share. Despite a slight slowdown in growth, Vertex's shares have risen nearly five percent in the past month, outpacing the broader therapeutics industry. With a target price of around four hundred eighty dollars, investors are watching closely to see if Vertex can maintain its momentum and potentially surprise the market.

The Daily News Now! — Every city. Every story. AI-powered.

---

Hosted on Acast. See acast.com/privacy for more information.